Guardant Health enhances cancer blood test capabilities

Guardant Health enhances cancer blood test capabilities#Guardant #Health #enhances #cancer #blood #test #capabilities

Merus N.V.'s SWOT analysis: promising cancer drug pipeline boosts stock outlook

Merus N.V.'s SWOT analysis: promising cancer drug pipeline boosts stock outlook#Merus #N.V.039s #SWOT #analysis #promising #cancer…

IMUNON’s Game-Changing Ovarian Cancer Data Sparks Massive Stock Surge – Here’s What You Need to Know!

Alright, folks, let’s talk about a stock that’s lighting up the market like a Fourth of…

Imunon shares soar on promising ovarian cancer trial results

Imunon shares soar on promising ovarian cancer trial results#Imunon #shares #soar #promising #ovarian #cancer #trial #results

Biden had not received prostate cancer screening since 2014, spokesperson says

Biden had not received prostate cancer screening since 2014, spokesperson says#Biden #received #prostate #cancer #screening #spokesperson

Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug

Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug#Pfizer #signs #billion…

Former US President Biden diagnosed with prostate cancer, his office says

Former US President Biden diagnosed with prostate cancer, his office says#President #Biden #diagnosed #prostate #cancer #office

Plus Therapeutics reports progress in CNS cancer therapy

Plus Therapeutics reports progress in CNS cancer therapy#Therapeutics #reports #progress #CNS #cancer #therapy

Serena-backed health tech lands first FDA approval for home cervical cancer test

For the first time, the FDA has just approved a device that lets people screen for…

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated…

Plans go in for £1bn cancer research centre in Sutton

CGI of the Gensler/Arup designed development Property investor Aviva Capital Partners (ACP) and mixed-use developer Socius…

Nuvalent reveals preclinical data on cancer drug zidesamtinib

Nuvalent reveals preclinical data on cancer drug zidesamtinib#Nuvalent #reveals #preclinical #data #cancer #drug #zidesamtinib

Early cancer detection startup Craif raises $22M

Cancer ranks as one of the top causes of death worldwide. The National Cancer Institute reported…

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO T

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade…

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer…

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small…

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients…

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer…

Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer#Pfizer039s #Sasanlimab #Combination…

Veracyte launches metastatic prostate cancer test

Veracyte launches metastatic prostate cancer test#Veracyte #launches #metastatic #prostate #cancer #test

RadNet to acquire AI cancer detection firm iCAD in stock deal

RadNet to acquire AI cancer detection firm iCAD in stock deal#RadNet #acquire #cancer #detection #firm #iCAD…

UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy

UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy #UroGen #June #PDUFA…